On Feb.11 Optimer  completed a 6M share offering of common stock at a price of $11.25 sh. and the stock has held up well despite the dilution. On February 7 the Company announced a deal with Astellas Pharmaceutical licensing off rights to their Fidaxomycin C.diff drug for Europe, parts of Africa and the Mid East.A recent publication in NEJM.org said the drug is comparable to Vancomycin with a lower rate of recurrence. An FDA action date is expected by May 30. Another product -Pruvel- is in the Phase III pipeline for travelers diarrhea. The stock may be volatile but the upcoming approval milestone combined with the strong balance sheet augers well for the Company.

Fidaxomicin versus Vancomycin for Clostridium difficile Infection — NEJM

%d bloggers like this: